The efficacy and safety of crizotinib in patients with ROS1 positive advanced stage NSCLC: The real-world experience from Turkey

Basit Öğe Kaydı
dc.contributor.authorKilickap, S.
dc.contributor.authorOlmez, O. F.
dc.contributor.authorCicin, I.
dc.contributor.authorDemirci, U.
dc.contributor.authorAlan, O.
dc.contributor.authorCabuk, D.
dc.contributor.authorSakalar, T.
dc.date.accessioned2024-02-23T14:45:11Z
dc.date.available2024-02-23T14:45:11Z
dc.date.issued2018
dc.departmentNEÜen_US
dc.description43rd ESMO Congress (ESMO) -- OCT 19-23, 2018 -- Munich, GERMANYen_US
dc.description.abstract[Abstract Not Availabe]en_US
dc.description.sponsorshipEuropean Soc Med Oncol,Japanese Soc Med Oncolen_US
dc.identifier.endpage505en_US
dc.identifier.issn0923-7534
dc.identifier.issn1569-8041
dc.identifier.scopusqualityQ1en_US
dc.identifier.startpage505en_US
dc.identifier.urihttps://hdl.handle.net/20.500.12452/17300
dc.identifier.volume29en_US
dc.identifier.wosWOS:000459277303171en_US
dc.identifier.wosqualityQ1en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.language.isoenen_US
dc.publisherOxford Univ Pressen_US
dc.relation.ispartofAnnals Of Oncologyen_US
dc.relation.publicationcategoryKonferans Öğesi - Uluslararası - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subject[Keyword Not Available]en_US
dc.titleThe efficacy and safety of crizotinib in patients with ROS1 positive advanced stage NSCLC: The real-world experience from Turkeyen_US
dc.typeConference Objecten_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu